BeyondSpring Inc. Reports <a href="https://laohu8.com/S/QTWO">Q2</a> 2025 Results: Net Loss Narrows to $1.9M, G&A Expenses Down by $0.9M
BeyondSpring Inc. has released its second-quarter 2025 financial results, highlighting a net loss of $1.9 million for the quarter ended June 2025, compared to a net loss of $2.7 million in the same period in 2024. The company's research and development expenses increased to $1.0 million from $0.8 million, reflecting higher professional service fees in regulatory and CMC activities, as well as increased costs for Plinabulin research. General and administrative expenses decreased to $0.9 million from $1.8 million, primarily due to lower professional service costs and reduced salary expenses driven by a decrease in administrative headcount. BeyondSpring also reported a net income of $1 million from discontinued operations for the six months ended June 2025, compared to a loss of $2.6 million for the same period in 2024. Additionally, BeyondSpring announced significant corporate updates, including the appointment of Dr. Bill Desmarais as the new CFO and CBO of SEED Therapeutics, which is progressing with its RBM39 degrader ST-01156 towards Phase 1 trials.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeyondSpring Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-25-005355), on August 13, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.